I
Iris Kao
Researcher at Novartis
Publications - 3
Citations - 954
Iris Kao is an academic researcher from Novartis. The author has contributed to research in topics: Cancer & Gene knockdown. The author has an hindex of 3, co-authored 3 publications receiving 747 citations.
Papers
More filters
Journal ArticleDOI
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald,Antoine de Weck,Michael R. Schlabach,Eric Billy,Konstantinos J. Mavrakis,Gregory R. Hoffman,Dhiren Belur,Deborah Castelletti,Elizabeth Frias,Kalyani Gampa,Javad Golji,Iris Kao,Li Li,Philippe Megel,Thomas A. Perkins,Nadire Ramadan,David A. Ruddy,Serena J. Silver,Sosathya Sovath,Mark Stump,Odile Weber,Roland Widmer,Jianjun Yu,Kristine Yu,Yingzi Yue,Dorothee Abramowski,Elizabeth Ackley,Rosemary Barrett,Joel Berger,Julie L. Bernard,Rebecca Billig,Saskia M. Brachmann,Frank Buxton,Roger Caothien,Justina X. Caushi,Franklin Chung,Marta Cortes-Cros,Rosalie deBeaumont,Clara Delaunay,Aurore Desplat,William Duong,Donald A. Dwoske,Richard S. Eldridge,Ali Farsidjani,Fei Feng,JiaJia Feng,Daisy Flemming,William C. Forrester,Giorgio G. Galli,Zhenhai Gao,François Gauter,Veronica Gibaja,Kristy Haas,Marc Hattenberger,Tami Hood,Kristen Hurov,Zainab Jagani,Mathias Jenal,Jennifer Johnson,Michael D. Jones,Avnish Kapoor,Joshua M. Korn,Jilin Liu,Qiumei Liu,Shumei Liu,Yue Liu,Alice T. Loo,Kaitlin J. Macchi,Typhaine Martin,Gregory McAllister,A. B. Meyer,Sandra Mollé,Raymond Pagliarini,Tanushree Phadke,Brian Repko,Tanja Schouwey,Frances Shanahan,Qiong Shen,Christelle Stamm,Christine Stephan,Volker M. Stucke,Ralph Tiedt,Malini Varadarajan,Kavitha Venkatesan,Alberto C. Vitari,Marco Wallroth,Jan Weiler,Jing Zhang,Craig Mickanin,Vic E. Myer,Jeffery A. Porter,Albert Lai,Hans Bitter,Emma Lees,Nicholas Keen,Audrey Kauffmann,Frank Stegmeier,Francesco Hofmann,Tobias Schmelzle,William R. Sellers +99 more
TL;DR: A large-scale RNAi screen is conducted in which viability effects of mRNA knockdown were assessed for 7,837 genes using an average of 20 shRNAs per gene in 398 cancer cell lines, outlining the classes of cancer dependency genes and their relationships to genetic, expression, and lineage features.
Journal ArticleDOI
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Hyo-eun C. Bhang,David A. Ruddy,Viveksagar Krishnamurthy Radhakrishna,Justina X. Caushi,Rui Zhao,Matthew M Hims,Angad P Singh,Iris Kao,Daniel P. Rakiec,Pamela Shaw,Marissa Balak,Alina Raza,Elizabeth Ackley,Nicholas Keen,Michael R. Schlabach,Michael Palmer,Rebecca Leary,Derek Y. Chiang,William R. Sellers,Franziska Michor,Vesselina G. Cooke,Joshua M. Korn,Frank Stegmeier +22 more
TL;DR: It is suggested that resistant clones are present before treatment, which would make up-front therapeutic combinations that target non-overlapping resistance a preferred approach and ClonTracer barcoding may be a valuable tool for optimizing therapeutic regimens with the goal of curative combination therapies for cancer.
Journal ArticleDOI
A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes
Qianhe Zhou,Adnan Derti,David A. Ruddy,Daniel P. Rakiec,Iris Kao,Michelle Lira,Veronica Gibaja,Ho Man Chan,Yi Yang,Junxia Min,Michael R. Schlabach,Frank Stegmeier +11 more
TL;DR: The Degron-KI system was able to faithfully recapitulate the effects of pharmacologic EZH2 and PI3Kα inhibitors in cancer cell lines and provided the first causal link between SF3B1 hotspot mutations and splicing alterations.